| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $595,487 | 12 | 86 |
Sells | $412,583 | 2 | 14 |
| KIRK THOMAS F | director | 8 | $448,347 | 0 | $0 | $448,347 |
| GUDONIS PAUL R | Chief Executive Officer | 2 | $143,907 | 0 | $0 | $143,907 |
| Crowley Thomas Aloysius Jr. | director | 2 | $3,233 | 0 | $0 | $3,233 |
| Kovelman Harry | Chief Medical Officer | 0 | $0 | 1 | $165,018 | $-165,018 |
| Mitchell Micah | Chief Commercial Officer | 0 | $0 | 1 | $247,565 | $-247,565 |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at Myomo, Inc. have bought $595,487 and sold $412,583 worth of Myomo, Inc. stock.
On average, over the past 5 years, insiders at Myomo, Inc. have bought $288,177 and sold $163,292 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KIRK THOMAS F (director) — $448,347. GUDONIS PAUL R (Chief Executive Officer) — $143,907. Crowley Thomas Aloysius Jr. (director) — $3,233.
The last purchase of 2,535 shares for transaction amount of $1,825 was made by KIRK THOMAS F (director) on 2025‑11‑21.
| 2025-11-21 | KIRK THOMAS F | director | 2,535 0.0062% | $0.72 | $1,825 | +31.12% | ||
| 2025-11-20 | KIRK THOMAS F | director | 4,902 0.0126% | $0.72 | $3,529 | +35.94% | ||
| 2025-11-19 | Crowley Thomas Aloysius Jr. | director | 385 0.001% | $0.77 | $295 | +35.34% | ||
| 2025-11-18 | Crowley Thomas Aloysius Jr. | director | 4,000 0.0104% | $0.73 | $2,938 | +35.64% | ||
| 2025-08-25 | KIRK THOMAS F | director | 50,000 0.1289% | $1.15 | $57,500 | -12.11% | ||
| 2025-08-18 | KIRK THOMAS F | director | 50,000 0.1299% | $1.10 | $55,000 | -12.78% | ||
| 2025-08-15 | GUDONIS PAUL R | Chief Executive Officer | 50,000 0.1254% | $0.95 | $47,295 | +0.22% | ||
| 2025-05-15 | GUDONIS PAUL R | Chief Executive Officer | 30,000 0.0831% | $3.22 | $96,612 | -66.87% | ||
| 2025-05-15 | KIRK THOMAS F | director | 36,824 0.103% | $3.25 | $119,678 | -66.87% | ||
| 2025-05-14 | KIRK THOMAS F | director | 1,943 0.0054% | $3.25 | $6,315 | -67.00% | ||
| 2025-05-12 | KIRK THOMAS F | director | 50,000 0.1402% | $3.35 | $167,500 | -67.62% | ||
| 2025-03-14 | Sale | Mitchell Micah | Chief Commercial Officer | 48,000 0.1387% | $5.16 | $247,565 | -77.84% | |
| 2025-03-13 | KIRK THOMAS F | director | 7,400 0.022% | $5.00 | $37,000 | -77.12% | ||
| 2025-03-12 | Sale | Kovelman Harry | Chief Medical Officer | 30,000 0.0914% | $5.50 | $165,018 | -78.64% | |
| 2024-09-05 | Sale | Kovelman Harry | Chief Medical Officer | 6,700 0.0221% | $3.76 | $25,183 | +8.49% | |
| 2024-09-03 | Sale | Kovelman Harry | Chief Medical Officer | 2,029 0.0069% | $4.01 | $8,140 | +5.14% | |
| 2024-05-29 | KIRK THOMAS F | director | 50,000 0.174% | $3.50 | $175,000 | +31.23% | ||
| 2024-05-15 | Sale | Kovelman Harry | Chief Medical Officer | 35,426 0.1201% | $3.69 | $130,839 | +21.16% | |
| 2024-03-14 | KIRK THOMAS F | director | 50,000 0.1683% | $3.50 | $175,000 | +15.26% | ||
| 2023-12-08 | Sale | Crowley Thomas Aloysius Jr. | director | 14,997 0.0571% | $4.08 | $61,188 | -4.27% |
| GUDONIS PAUL R | Chief Executive Officer | 1259013 3.2795% | $1.21M | 11 | 0 | +92.18% |
| KIRK THOMAS F | director | 481857 1.2552% | $463,690.99 | 13 | 0 | <0.0001% |
| Mitchell Micah | Chief Commercial Officer | 140269 0.3654% | $134,980.86 | 1 | 3 | +66.14% |
| Kovelman Harry | Chief Medical Officer | 97973 0.2552% | $94,279.42 | 1 | 5 | +335.91% |
| Crowley Thomas Aloysius Jr. | director | 479 0.0012% | $460.94 | 2 | 8 | |
| HENRY DAVID A | Chief Financial Officer | 352193 0.9174% | $338,915.32 | 5 | 0 | +62.8% |
| SANGHI STEVE | director | 298513 0.7776% | $287,259.06 | 1 | 0 | <0.0001% |
| Morris Milton Mayo | director | 77933 0.203% | $74,994.93 | 1 | 0 | +227.36% |
| Naft Jonathan | VP, GENERAL MANAGER | 74114 0.1931% | $71,319.90 | 1 | 0 | <0.0001% |
| Increased Positions | 33 | +29.2% | 2M | +11.67% |
| Decreased Positions | 50 | -44.25% | 8M | -40.9% |
| New Positions | 14 | New | 781,314 | New |
| Sold Out Positions | 29 | Sold Out | 7M | Sold Out |
| Total Postitions | 96 | -15.04% | 14M | -29.23% |
| Rosalind Advisors, Inc. | $3,753.00 | 9.98% | 3.79M | +195,000 | +5.42% | 2025-09-30 |
| Blackrock, Inc. | $1,648.00 | 4.38% | 1.66M | -11,485 | -0.69% | 2025-09-30 |
| Vanguard Group Inc | $1,470.00 | 3.91% | 1.49M | -2,939 | -0.2% | 2025-09-30 |
| Goldman Sachs Group Inc | $1,023.00 | 2.72% | 1.03M | +666,493 | +181.56% | 2025-09-30 |
| Geode Capital Management, Llc | $796.00 | 2.12% | 804,434 | +135,153 | +20.19% | 2025-09-30 |
| Renaissance Technologies Llc | $705.00 | 1.87% | 712,094 | +170,689 | +31.53% | 2025-09-30 |
| Soleus Capital Management, L.P. | $697.00 | 1.85% | 704,275 | 0 | 0% | 2025-09-30 |
| Clearstead Advisors, Llc | $421.00 | 1.12% | 425,600 | +11 | +<0.01% | 2025-09-30 |
| State Street Corp | $376.00 | 1% | 380,290 | +38,465 | +11.25% | 2025-09-30 |
| Aqr Capital Management Llc | $291.00 | 0.77% | 293,949 | +293,949 | New | 2025-09-30 |